CARB-X announced Tuesday an award of up to $3.6 million (plus up to $10.2 million in milestones) to Maryland-based Novel Microdevices to develop a rapid, point-of-care, battery-powered diagnostic for sexually transmitted infections such as chlamydia and gonorrhea.

The test—which will also identify antibiotic resistance—will diagnose infections in about 25 minutes from a vaginal swab or urine sample and require no sample preparation, making it “particularly suited” for LMICs, according…

CARB-X announced Monday an award of up to $2 million and up to $5.3 million more in milestones to the University of Oxford’s Jenner Institute for work on its gonorrhea vaccine candidate (dmGC_0817560 NOMV), currently in lead optimization.

The funds will support optimization, scale-up and production for first-in-human trials of “an affordable vaccine for global use,” the press release said.

The Geneva-based Global Antibiotic Research and Development Partnership (GARDP) announced last week that it has signed a memorandum of understanding with India’s Dr. Reddy’s and Aurigene Pharmaceutical Services to explore joint opportunities to make novel drug-resistant gonorrhea treatment zoliflodacin “accessible in low- and middle-income countries (LMICs), including South Africa, Thailand and India.”

The press release did not detail deal terms outside of GARDP’s responsibility to…

Netherlands-based Intravacc announced Tuesday that its partner Therapyx has won $2.8 million in U.S. government funding to continue preclinical development of their jointly developed N. gonorrhoeae mucosal vaccine.

Intravacc’s press release said the mucosal platform could also target “challenging respiratory viral infections,” including COVID-19.

CARB-X announced this week that it is awarding Massachusetts-based Microbiotix up to $2.86 million upfront and as much as $16 million in potential milestone payments to develop a novel oral antibiotic to treat multidrug-resistant gonorrhea.

In 2017, the Boston University-led consortium also awarded Microbiotix $3.2 million to develop novel inhibitors against resistant P. aeruginosa in pneumonia.

CARB-X announced this week that it is giving Pennsylvania-based VenatoRx up to $4.1 million upfront and $8.9 million more in potential milestone payments to develop a new class of oral antibiotics to treat infections caused by multidrug-resistant Neisseria gonorrhoeae.

Last year, CARB-X also awarded Summit Therapeutics up to $4.5 million to develop new antibiotic compounds against gonorrhea.

Defying a big pharma trend of abandoning antibiotic R&D, GSK announced this week that it has started Phase 3 trials of a first-in-class antibiotic, gepotidacin, in patients with acute cystitis and gonorrhea. The company expects initial results by the end of 2021.

In other news, the U.S. National Institute of Allergy and Infectious Diseases has awarded the University of Alabama at Birmingham $10 million to carry out Phase 2 trials to test the effectiveness of GSK’s meningitis B…

The nonprofit Global Antibiotic Research and Development Partnership (GARDP) and Entasis Therapeutics announced this week that they are starting Phase 3 trials of the Massachusetts-based company’s new oral antibiotic for the treatment of uncomplicated gonorrhea.

GARDP is fully funding the trials, which plan to enroll 1,000 adults with urogenital gonorrhea across four countries, a joint press release said. The results (expected in 2021) will compare zoliflodacin against the current…

Intravacc announced this week that it is setting up a private company as the first step towards complete privatization of the state-owned Dutch vaccine research and development organization. According to a press release, once shares are sold to the selected buyer, Intravacc will transfer assets, staff and contracts to the newly formed Intravacc B.V., ensuring a smooth transition.

The company is currently engaged with Serum Institute of India and other manufacturers to develop measles-…

The Geneva-based Foundation for Innovative New Diagnostics (FIND) announced at the AMR Call to Action meeting in Ghana this week that it is launching a Diagnostics Use Accelerator with support from Britain’s and Switzerland’s development agencies.

FIND said former head of intervention and implementation research at WHO’s Special Programme for Research & Training in Tropical Diseases, Professor Piero Olliaro, will lead the demonstration study platform with the goal of speeding up “…